J
Jamie Cavenagh
Researcher at St Bartholomew's Hospital
Publications - 191
Citations - 14894
Jamie Cavenagh is an academic researcher from St Bartholomew's Hospital. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 52, co-authored 174 publications receiving 13488 citations. Previous affiliations of Jamie Cavenagh include St George's Hospital & Queen Mary University of London.
Papers
More filters
Journal ArticleDOI
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
Paul G. Richardson,Pieter Sonneveld,Michael W. Schuster,D. Irwin,Edward A. Stadtmauer,Thierry Facon,Jean-Luc Harousseau,Dina Ben-Yehuda,Sagar Lonial,Hartmut Goldschmidt,Donna E. Reece,Jesús F. San-Miguel,Joan Bladé,Mario Boccadoro,Jamie Cavenagh,William S. Dalton,Anthony Boral,Dixie Lee Esseltine,Jane B. Porter,David P. Schenkein,Kenneth C. Anderson +20 more
TL;DR: Bortezomib is superior to high-dose dexamethasone for the treatment of patients with multiple myeloma who have had a relapse after one to three previous therapies.
Journal ArticleDOI
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Jesús F. San-Miguel,V. Hungria,Sung-Soo Yoon,Meral Beksac,Meletios A. Dimopoulos,Ashraf Elghandour,Wiesław Wiktor Jędrzejczak,Andreas Günther,Thanyaphong Na Nakorn,Noppadol Siritanaratkul,Paolo Corradini,Suporn Chuncharunee,Je-Jung Lee,Robert L. Schlossman,Tatiana Shelekhova,Kwee Yong,Daryl Tan,Tontanai Numbenjapon,Jamie Cavenagh,Jian Hou,Richard Leblanc,Hareth Nahi,Lugui Qiu,Hans Salwender,Stefano Pulini,Philippe Moreau,Krzysztof Warzocha,Darrell White,Joan Bladé,Wenming Chen,Javier de la Rubia,Peter Gimsing,Sagar Lonial,Jonathan L. Kaufman,Enrique M. Ocio,Ljupco Veskovski,Sang Kyun Sohn,Ming Chung Wang,Jae Hoon Lee,Hermann Einsele,Monika Sopala,Claudia Corrado,Bourras Rezki Bengoudifa,Florence Binlich,Paul G. Richardson +44 more
TL;DR: Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical studies has synergistic anti-myeloma activity when combined with bortezomib and dexamethasone and the proportion of patients achieving an overall response did not differ between treatment groups.
Journal ArticleDOI
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma
Lotfi Benboubker,Meletios A. Dimopoulos,Angela Dispenzieri,John Catalano,Andrew Belch,Michele Cavo,Antonello Pinto,Katja Weisel,Heinz Ludwig,Nizar J. Bahlis,Anne Banos,Mourad Tiab,Michel Delforge,Jamie Cavenagh,Catarina Geraldes,Je-Jung Lee,Christine Chen,Albert Oriol,Javier de la Rubia,Lugui Qiu,Darrell White,Daniel Binder,Kenneth C. Anderson,Jean Paul Fermand,Philippe Moreau,Michel Attal,Robert Knight,Guang Chen,Jason Van Oostendorp,Christian Jacques,Annette Ervin-Haynes,Hervé Avet-Loiseau,Cyrille Hulin,Thierry Facon +33 more
TL;DR: Continuous lenalidomide-dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation.
Journal ArticleDOI
Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia
Nicolas Goardon,Emanuele Marchi,Ann Atzberger,Lynn Quek,Anna Schuh,Shamit Soneji,Petter S. Woll,Adam J. Mead,Kate A. Alford,R Rout,Salma Chaudhury,Amanda F. Gilkes,Steven Knapper,Kheira Beldjord,Suriya Begum,Susan Rose,Nicola Geddes,Mike Griffiths,Graham R. Standen,Alexander Sternberg,Jamie Cavenagh,Hannah Hunter,David G. Bowen,Sally Killick,L. G. Robinson,Andrew Price,Elizabeth Macintyre,Paul Virgo,Alan Kenneth Burnett,Charles Craddock,Tariq Enver,Sten Eirik W. Jacobsen,Catherine Porcher,Paresh Vyas +33 more
TL;DR: It is shown that in ∼80% of primary human CD34+ acute myeloid leukemia (AML), two expanded populations with hemopoietic progenitor immunophenotype coexist in most patients, suggesting that in most cases primaryCD34+ AML is a progenitors disease where LSCs acquire abnormal self-renewal potential.
Journal ArticleDOI
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Paul G. Richardson,Pieter Sonneveld,Michael W. Schuster,David Irwin,Edward A. Stadtmauer,Thierry Facon,Jean-Luc Harousseau,Dina Ben-Yehuda,Sagar Lonial,Hartmut Goldschmidt,Donna E. Reece,Jesús F. San Miguel,Joan Bladé,Mario Boccadoro,Jamie Cavenagh,Melissa Alsina,Vincent Rajkumar,Martha Q. Lacy,Andrzej Jakubowiak,William S. Dalton,Anthony Boral,Dixie-Lee Esseltine,David P. Schenkein,Kenneth C. Anderson +23 more
TL;DR: The activity of bortezomib is confirmed and support extended treatment in relapsed multiple myeloma patients tolerating therapy and among responding patients, 56% improved response with longer therapy beyond initial response, leading to continued improvement in overall quality of response.